LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art Co.Lab facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation.
This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours.
'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer Co.Lab offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences.
Fiona Mack, Head Co.Lab Cambridge at Bayer HealthCare LLC said: 'The Co.Lab was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. Co.Lab portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.'
As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely.
About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering.
The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See www.LIfTBiosciences.com
Further informationInvestors:Alex Blyth ablyth@LIfTBioSciences.com
Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@icrhealthcare.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 days ago
- Business Wire
OFS Credit Company Provides July 2025 Net Asset Value Update
CHICAGO--(BUSINESS WIRE)--OFS Credit Company, Inc. (Nasdaq: OCCI) ('OFS Credit', the 'Company', 'we', 'us' or 'our'), an investment company that primarily invests in collateralized loan obligation ('CLO') equity and debt securities, today announced the following net asset value ('NAV') estimate at July 31, 2025. Management's unaudited estimate of the range of our NAV per share of our common stock at July 31, 2025 is between $6.08 and $6.18. This estimate is not a comprehensive statement of our financial condition or results for the month ended July 31, 2025. This estimate did not undergo the Company's typical quarter-end financial closing procedures. We advise you that the final determination of our NAV per share as of July 31, 2025, which will be reported in our monthly report on Form N-PORT, may differ from this estimate. Our financial condition, including the fair value of our portfolio investments, and results of operations may be materially impacted after July 31, 2025 by circumstances and events that are not yet known. To the extent our portfolio investments are adversely impacted by interest rate and inflation rate changes, the ongoing war between Russia and Ukraine, the escalated armed conflict and heightened regional tensions in the Middle East, the agenda of the U.S. Presidential administration, including the impact of tariff enactment and tax reductions, trade disputes with other countries, instability in the U.S. and international banking systems, the risk of recession or a shutdown of U.S. government services and related market volatility, or by other factors, we may experience a material adverse impact on our future NAV, net investment income, the underlying value of our investments, our financial condition and the financial condition of our portfolio investments. The preliminary financial data included in this press release has been prepared by, and is the responsibility of, OFS Credit's management. KPMG LLP has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, KPMG LLP does not express an opinion or any other form of assurance with respect thereto. About OFS Credit Company, Inc. OFS Credit is a non-diversified, externally managed closed-end management investment company. The Company's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation, which we seek to achieve primarily through investments in CLO equity and debt securities. The Company's investment activities are managed by OFS Capital Management, LLC, an investment adviser registered under the Investment Advisers Act of 1940 1, as amended, and headquartered in Chicago, Illinois with additional offices in New York and Los Angeles. Forward-Looking Statements Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects may constitute forward-looking statements. Forward-looking statements can be identified by terminology such as 'anticipate', 'believe', 'could', 'could increase the likelihood', 'estimate', 'expect', 'intend', 'is planned', 'may', 'should', 'will', 'will enable', 'would be expected', 'look forward', 'may provide', 'would' or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in documents that may be filed by OFS Credit from time to time with the Securities and Exchange Commission, as well as interest rate and inflation rate changes, the ongoing war between Russia and Ukraine, the escalated armed conflict and heightened regional tensions in the Middle East, the agenda of the U.S. Presidential administration, including the impact of tariff enactment and tax reductions, trade disputes with other countries, instability in the U.S. and international banking systems, the risk of recession or a shutdown of U.S government services and related market volatility on our business, our portfolio companies, our industry and the global economy. As a result of such risks, uncertainties and factors, actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. OFS Credit is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 1 Registration does not imply a certain level of skill or training OFS® and OFS Credit® are registered trademarks of Orchard First Source Asset Management, LLC. OFS Capital Management™ is a trademark of Orchard First Source Asset Management, LLC.
Yahoo
4 days ago
- Yahoo
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market
-- U.S.-India focused clinical-stage pharmaceutical maker Vyome Holdings (Nasdaq: HIND) rang the opening bell at the NASDAQ on Friday, celebrating Indian Independence Day and its trading debut after a reverse merger with ReShape Lifesciences. Shares of HIND last traded at $13.15, down 16%. The company is targeting the immuno-inflammatory market in the US and globally, valued at $100 billion. "The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our stock being on Nasdaq," said Krishna Gupta, Chairman of Vyome. Co-founder Shiladitya Sengupta, who also serves as Associate Professor of Medicine at Harvard Medical School, pointed to the company's "very deep" innovation pipeline and access to talent in both the United States and India. On how the US-India tech and innovation pipeline positions the company for growth, Gupta exclusively told 'The company has a pipeline of clinical stage assets; for each, Vyome has a plan to unlock value over the next 12-24 months. The research is being done collaboratively across India and the US.' The company decided to go public via a reverse merger versus the traditional route because they 'felt like it would be an easier and more efficient path if we could find a very clean public shell, which we did,' Gupta added. 'We were confident that opening up access to our vision to the entire world was the way we wanted to build the company going forward.' The Chairman doesn't feel the recently strained U.S./India relationship related to tariffs and Russian oil will have a negative impact on the company. 'It hasn't, nor do we think the relationship will be strained much longer - it's crazy to think that may be a contrarian view at this specific moment,' Gupta said in response to a question about whether the strained U.S./India relationship impacts the company. 'This is the defining partnership of the times, and the US and India will remain friends and collaborators, particularly in innovation-related endeavors.' Related articles Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market Opendoor stock jumps after CEO exit, retail activists claim win The race for sovereign AI is intensifying. Here's what you need to know Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Journals
4 days ago
- Business Journals
Ridgefield plans to limit lines for Washington's first In-N-Out
The city fears the In-N-Out, planned to open in September, could cause traffic backups blocking public roads.
